Page 2 - Pharmaceutical Firms

Innovator drugs maintain market hold even after patent expiry, shows data

Merck's anti-diabetic molecule sitagliptin retains 81% market share in value terms

Viatris deal gives Biocon Biologics entry in 100 countries: Shreehas Tambe

In a Q&A, the recently named MD & CEO of Biocon Biologics dwells on the scope for an IPO or stake sale to PE investors to retire the debt taken to fund the acquisition

Price war begins for Novartis cardiac drug as JB Pharma cuts rate by 50%

Novartis' blockbuster drug is set to lose patent in Jan; JB Pharma, one of the four marketers in India of generi versions, has slashed the price of its brand Azmarda to Rs 39.6 a tablet

Lessons from Covid: Pharma firms turn attention to adult vaccination

Vaccine companies have warmed up to the idea of adult vaccines for other diseases such as pneumonia, flu and shingles as well

Pharma, consumer durables sectors likely to feel China curb heat

Industry players say lockdown could have an impact on the supply of components used in consumer durables

Fosun plans to sell of India's $3.8 billion drug maker Gland Pharma

Fosun Pharma, a listed arm of Chinese conglomerate Fosun International Ltd., has been working with an adviser as it informally gauges interest in its controlling stake in Gland, the people said

Orchid Pharma antibiotic product for treating UTI coming to India: MD

Company says it's returning to profit after takeover by Dhanuka Laboratories under insolvency resolution

SK Bioscience suspends production of Covid-19 vaccine 'Sky Covione'

It previously obtained item approval on June 29 and supplied vaccines on September under a pre-purchase contract with the government, but suspended production due to low market demand

World's most expensive drug approved to treat Hemophilia at $3.5 mn a dose

CSL Behring's Hemgenix, administered just once, cut the number of bleeding events expected over the course of a year by 54%, a key study of the therapy found

Top 300 drug brands to now have QR codes on label for ensuring authenticity

Govt finalises the draft notification issued in June

A viral message in the Moderna story

In The Messenger, The Wall Street Journal reporter Peter Loftus charts the journey of Moderna from being a languishing biotech start-up to one of the biggest financial beneficiaries of the pandemic

CM Basavaraj Bommai emphasises cooperation with US in pharma sector

Chief Minister Basavaraj Bommai emphasized the importance of setting up a working group between US officials and the Karnataka government for increasing pharma-related R & D as well as drug production in the state.He was interacting with a delegation led by Rahul Gupta, Director of the White House Office of National Drug Control Policy at his Home Office Krishna. Rahul Gupta explained in detail the measures President Joe Biden's Office took to increase cooperation between India and the USA in Drug Policy Formulation and Drug production and in the field of Narcotic Drugs Control.He agreed to initiate necessary dialogue in this direction and sought the indulgence of CM Bommai to facilitate more investments by US companies in the Pharma sector in Karnataka.CM Bommai stated that Karnataka has already become a hub of drug research and welcomed more investments by US companies in drug and vaccine production for the world.The US delegation included Harinder S. Panesar, President of the ..

Trying to lock in vendors who don't want to buy from China: Biocon CEO & MD

Siddharth Mittal, CEO & MD, Biocon, elaborates on his plans to grow this business further

Biocon Q2 results: Net profit declines 10% to Rs 168 crore, revenue up 26%

Biocon's core Ebitda came in at Rs 816 crore, up 34 per cent

Alembic Pharma gets USFDA nod for generic cancer treatment medication

Alembic Pharmaceuticals on Monday said it has received approval from the US health regulator to market Cyclophosphamide capsules, used in the treatment of different kinds of cancers, in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market its product which is a generic version of Hikma Pharmaceuticals USA Inc product, Alembic Pharmaceuticals said in a statement. Cyclophosphamide capsules is an alkylating drug indicated for the treatment of malignant disease and minimal change nephrotic syndrome in pediatric patients. According to IQVIA, cyclophosphamide capsules, 25 mg and 50 mg, have an estimated market size of USD 8 million in the US for twelve months ending Sep 2022. Shares of the drug firm were trading 1.32 per cent down at Rs 630.35 apiece on the BSE.

Piramal Enterprises posts net loss of Rs 1,536 cr on higher provisions

PEL has moved Rs 5,888 crore worth of wholesale assets from Stage 1 to Stage 2 as the management believed there could be potential stress from these assets

Zydus gets establishment inspection report from USFDA for Moraiya plant

Zydus Lifesciences on Monday said it has received an establishment inspection report from the US health regulator for its formulations manufacturing facility in Moraiya near Ahmedabad. The US Food and Drug Administration (USFDA) inspected the facility from July 26 to August 5, 2022, which concluded with four observations. "The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)," it added. The USFDA issues an establishment inspection report (EIR) to an establishment that is the subject of an FDA or FDA-contracted inspection when the agency decides to close the inspection. Shares of Zydus Lifesciences were trading 2.51 per cent up at Rs 450.85 apiece on the BSE.

Chhattisgarh govt's flagship scheme delivers hefty markdown on medicines

The state government has given priority to the health security of the people, the official said

We thrive on products that have limited competition: Top Sun Pharma execs

In a Q&A, the firm's US business head and its group CFO talk about their plans to scale the specialty products business further, and dwell on the company's strategies post-pandemic

Sun Pharma Q2 PAT rises 10.5% YoY to Rs 2,262 crore on robust sales

Gross sales came in at Rs 10,809.2 crore, growing by 13.1% over Q2 last year